文献速递胃肠动力与功能性疾病

胃生理与动力障碍中的5-羟色胺能信号

Serotonergic Signaling in Gastric Physiology and Motility Disorders.
PubMed 文献 · Gastroenterology · 2026-07-22

本文综述5-羟色胺(5-HT)在胃生理与动力障碍中的作用。5-HT由肠嗜铬细胞释放,调节胃感觉运动功能并参与肠神经发生。国际指南支持5-HT4激动剂用于胃轻瘫,5-HT3拮抗剂控制恶心呕吐;功能性消化不良可基于症状选择性超说明书使用米氮平或丁螺环酮。新型选择性5-HT4激动剂naronapride显示临床相关获益并可能减少心血管风险,但尚缺乏大型对照试验。

要点

  • 5-HT4激动剂是国际指南中胃轻瘫最一致支持的5-HT能药物。
  • 5-HT3拮抗剂主要用于胃轻瘫恶心呕吐的症状控制。
  • 功能性消化不良可基于症状超说明书选用米氮平或丁螺环酮。

核心结论

  • 5-HT能信号改变是胃动力障碍病理生理的重要贡献因素和治疗靶点。
  • 5-HT4激动剂对胃轻瘫有改善胃排空和症状的证据,5-HT3拮抗剂主要用于恶心呕吐症状控制。
  • 功能性消化不良可基于症状特征选择性超说明书使用米氮平或丁螺环酮。
  • SSRI和SNRI不推荐用于胃轻瘫或功能性消化不良,但值得进一步研究。
  • 尚缺乏评估5-HT能药物治疗胃轻瘫和功能性消化不良疗效的大型对照试验。

研究设计与样本

  • 综述整合分子、生理和临床数据,阐明5-HT能信号在胃生理与动力障碍中的相关性、治疗应用和证据缺口。

主要发现

  • 5-HT主要由肠嗜铬细胞释放,肠嗜铬细胞作为特化的上皮化学和机械感受器。
  • 在人类中5-HT调节胃感觉运动功能,动物研究提示其参与肠神经发生。
  • 早期5-HT能药物如西沙必利因安全性担忧被撤市,新型受体特异性配体已可用。
  • naronapride为新型5-HT4激动剂,近期数据提示更选择性药物可能提供临床相关获益并减轻早期药物的心血管安全风险。

关键数值与推荐

  • 胃轻瘫:5-HT4激动剂是国际指南中最一致支持的5-HT能药物,有改善胃排空和症状的证据。
  • 胃轻瘫:5-HT3拮抗剂主要用于恶心呕吐的症状控制。
  • 功能性消化不良:早饱伴体重减轻者可超说明书考虑米氮平(5-HT2拮抗剂)。
  • 功能性消化不良:早饱、餐后饱胀或腹胀者可超说明书考虑丁螺环酮(5-HT1A激动剂)。
  • SSRI和SNRI不推荐用于胃轻瘫或功能性消化不良。

临床怎么用

  • 胃轻瘫管理优先考虑5-HT4激动剂,以其改善胃排空和症状的证据为基础。
  • 胃轻瘫恶心呕吐可用5-HT3拮抗剂进行症状控制。
  • 功能性消化不良按症状特征超说明书选择米氮平或丁螺环酮。
  • 避免将SSRI或SNRI用于胃轻瘫或功能性消化不良。
  • 关注naronapride等新型选择性5-HT4激动剂的证据发展。

局限性

  • 评估5-HT能药物在胃轻瘫和功能性消化不良中疗效的大型对照试验仍缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serotonin (5-hydroxytryptamine [5-HT]) is a key regulator of gastrointestinal function and exerts its effects through a diversity of 5-HT receptors. In the gut, 5-HT is released primarily by enterochromaffin cells, which act as specialized epithelial chemo- and mechanosensors. In humans, 5-HT modulates gastric sensorimotor function, and animal studies suggest that it is involved in enteric neurogenesis. Altered serotonergic signaling is increasingly recognized as an important contributor to the pathophysiology of gastric motility disorders and, therefore, represents an important therapeutic target. Although early serotonergic agents such as cisapride were withdrawn due to safety concerns, newer receptor-specific ligands have become available, broadening the therapeutic landscape and underscoring the need for an updated synthesis of serotonergic pathways and therapies in gastric motility disorders. For the management of gastroparesis, 5-HT4 agonists are the most consistently supported serotonergic agents in international guidelines, with evidence for improving gastric emptying and symptoms, and 5-HT3 antagonists are used primarily for symptomatic control of nausea and vomiting. In functional dyspepsia, serotonergic therapies may be selectively considered for off-label use based on the symptom profile, including mirtazapine (a 5-HT2 antagonist) in patients with early satiety and weight loss, and buspirone (a 5-HT1A agonist) in those with early satiety, postprandial fullness, or bloating. Although selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors are not recommended for use in gastroparesis or functional dyspepsia, their potential role warrants further investigation, particularly given their established efficacy in conditions with chronic pain. Large, controlled trials evaluating the efficacy of serotonergic agents in gastroparesis and functional dyspepsia remain lacking, but recent developments highlight the continued relevance of serotonergic modulation. Recent data on naronapride, a newer 5-HT4 agonist, suggest that more selective agents may offer a clinically relevant benefit, while mitigating cardiovascular safety risks associated with earlier agents. By integrating molecular, physiological, and clinical data, this review aims to clarify the relevance of serotonergic signaling in gastric physiology and motility disorders, define its therapeutic applications, and identify the key remaining evidence gaps.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Konings B, Balsiger LM, Schol J, et al. Serotonergic Signaling in Gastric Physiology and Motility Disorders. Gastroenterology. 2026. PMID: 42486340. doi:10.1053/j.gastro.2026.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。